Gene therapy: Regulations, ethics and its practicalities in liver disease

World Journal of Gastroenterology

Volumn 14, Issue 15, 2008, Pages 2303-2307

  Jin, Xi ^a   Yang, Yi Dang ^a   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gene therapy; Hepatocarcinoma; Liver disease; Vector

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ADENOVIRUS VECTOR; CD40 LIGAND; CYSTEINYLASPARTYLCYSTEINYLARGINYLGLYCYLASPARTYLCYSTEINYLPHENYLALANYLCYSTEINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; LENTIVIRUS VECTOR; MIFEPRISTONE; PARVOVIRUS VECTOR; POLYPEPTIDE; RETROVIRUS VECTOR;

CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CRIGLER NAJJAR SYNDROME; DRUG MECHANISM; GENE THERAPY; GENE TRANSFER; GERM LINE GENE THERAPY; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER METASTASIS; LIVER TUMOR; MEDICAL ETHICS; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; SOMATIC GENE THERAPY; SUICIDE GENE THERAPY; VIRAL GENE THERAPY;

EID: 45849116494     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2303     Document Type: Review

References (52)

1. Blau HM, Springer ML. Gene therapy-a novel form of drug delivery. N EngI J Med 1995; 333: 1204-1207
2. Lundstrom K, Boulikas T. Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2003; 2: 471-486
3. Williams DA, Baum C. Medicine. Gene therapy--new challenges ahead. Science 2003; 302: 400-401
4. Li Zz, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K Eckert HG, Fehse B,,Baum C. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497
5. Spink J, Geddes D. Gene therapy progress and prospects: bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment. Gene Ther 2004; 11: 1611-1616
6. Resnik DB, Langer PJ. Human germline gene therapy reconsidered. Hum Gene Ther 2001; 12: 1449-1458
7. Gottschalk U, Chan S. Somatic gene therapy. Present situation and future perspective. Arzneimittelforschung 1998; 48: 1111-1120
8. Walters L. Human gene therapy: ethics and public policy. Hum Gene Ther 1991; 2: 115-122
9. Seifter S, Englard S. Energy metabolism. The liver-Biology and Pathology. 3rd ed. New York: Raven Press, 1994:323-364
10. Richardson PD, Kren BT, Steer CJ. Gene repair in the new age of gene therapy. Hepatology 2002; 35: 512-518
11. Askari FK, Hitomi Y, Mao M, Wilson JM. Complete correction of hyperbilirubinemia in the Gunn rat model of Crigler-Najjar syndrome type I following transient in vivo adenovirus-mediated expression of human bilirubin UDP- glucuronosyltransferase. Gene Ther 1996, 3: 381-388
12. Askari F, Hitomi Y, Thiney M, Wilson JM. Retrovirus-mediated expression of HUG Br1 in Crigler-Najjar syndrome type I human fibroblasts and correction of the genetic defect in Gunn rat hepatocytes. Gene Ther 1995; 2: 203-208
13. Conlon TJ, Walter G, Owen R, Cossette T, Erger K, Gutierrez G, Goetzman E, Matern D, Vockley J, Flotte TR. Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector. Hum Gene Ther 2006; 17: 71-80
14. Chengalvala MV, Lubeck MD, Selling BJ, Natuk RJ, Hsu KH, Mason BB, Chanda PK, Bhat RA, Bhat BM, Mizutani S. Adenovirus vectors for gene expression. Curr Opin Biotechnol 1991; 2: 718-722
15. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999; 6: 113-138
16. Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999; 10: 2451-2459
17. Goncalves MA, van der Velde I, Knaan-Shanzer S, Valerio D, de Vries AA. Stable transduction of large DNA by high-capacity adeno-associated virus/adelnovirus hybrid vectors. Virology 2004; 321: 287-296
18. D'Souza V, Summers MF. How rptroviruses select their genomes. Nat Rev Microbiol 2005; 3: 643-655
19. Bushman F, Lewinski M, Ciuffi A, Barr S, Leipzig J, Hannenhalli S, Hoffmann C. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol 2005; 3: 848-858
20. Romano G. Current development of lentiviral-mediated gene transfer. Drug Neivs Perspect 2005; 18: 128-134
21. McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 2005; 5: 333-338
22. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther 2005; 5: 349-360
23. Flotte TR. Recent developments in recombinant AAV- mediated gene therapy for lung diseases. Curr Gene Ther 2005; 5: 361-366
24. Dinculescu A, Glushakova L, Min SH, Hauswirth WW. Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 2005; 16: 649-663
25. Romano G. Current development of adeno-associated viral vectors. Drug News Perspect 2005; 18: 311-316
26. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005; 5: 323-331
27. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004; 4: 357-372
28. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9: 147-1652
29. Ma H, Diamond SL. Nonviral gene therapy and its delivery systems. Curr Pharm Biotechnol 2001; 2: 1-17
30. Li S, Ma Z. Nonviral gene therapy. Curr Gene Ther 2001; 1: 201-226
31. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3: 8-24
32. Prieto J, Herraiz M, Sangro B, Qian , Mazzolini G, Melero I, Ruiz J. The promise of gene therapy in gastrointestinal and liver diseases. Gut 2003; 52 SuppI 2: ii49-ii54
33. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des 2003; 9: 1981-1991
34. Shurin MR, Esche C, Peron JM, Lotze MT. Antitumor activities of IL-12 and mechanisms of action. Chem Immunol 1997; 68: 153-174
35. Lui VW, Falo LD Jr, Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J Gene Med 2001; 3: 384-393
36. Barajas M, Mazzolini G, Genove G. Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33: 52-61
37. Wang L, Hernandez-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, Kramer MG, Prieto J, Qian C. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 2004; 126: 278-289
38. Waehler R, Ittrich H, Mueller L, Krupski G, Ameis D, Schnieders F. Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12. Hum Gene Ther 2005; 16: 307-317
39. Dickerson EB, Akhtar N, Steinberg H, Wang ZY, Lindstrom MJ, Padilla ML, Auerbach R, Helfand SC. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2004; 2: 663-673
40. Su W, Kitagawa T, Ito T, Oyama T, Lee CM, Kim YK, Matsuda H. Antitumor effect to IL-12 administration into the portal vein on murine liver metastasis. J Hepatobiliary Pancreat Surg 2002; 9: 503-510
41. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000; 164: 3112-3122
42. Huttner KG, Breuer SK, Paul P, Majdic O, Heitger A, Felzmann T. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 2005; 54: 67-77
43. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2: 337-349
44. Itokawa Y, Mazda O, Ueda Y, Kishida T, Asada H, Cui FD, Fuji N, Fujiwara H, Shin-Ya M, Yasutomi K, Imanishi J, Yamagishi H. Interleukin-12 genetic administration suppressed metastatic liver tumor unsusceptible to CTL. Biochem Biophys Res Commun 2004; 314: 1072-1079
45. Weber SM, Qi C, Neal Z, Sondel P, Mahvi DM. IL-12 cDNA direct injection: antimetastatic effect from a single injection in a murine hepatic metastases model. J Surg Res 2004; 122: 210-217
46. Siders WM, Wright PW, Hixon JA, Alvord WG, Back TC, Wiltrout RH, Fenton RG. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J Immunol 1998; 160: 5465-5474
47. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23: 66-77
48. Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 2000; 7: 1467-1476
49. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000; 60: 6391-6395
50. Takahashi Y, Nishikawa M, Kobayashi N, Takakura Y. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J Control Release 2005; 105: 332-343
51. van Etten B, Eggermont AM, van Tiel ST, Ambagtsheer G, de Wilt JH, ten Hagen TL. Gene therapy in in vivo isolated perfusion models. Curr Gene Ther 2005; 5: 195-202
52. Terazaki Y, Yano S, Yuge K, Nagano S, Fukunaga M, Guo ZS, Komiya S, Shirouzu K, Kosai K. An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. Hepatology 2003; 37: 155-163